Literature DB >> 14662531

Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy.

Lorenzo Capussotti1, Paolo Massucco, Dario Ribero, Luca Viganò, Andrea Muratore, Marco Calgaro.   

Abstract

HYPOTHESIS: An aggressive strategy that includes extended lymphadenectomy and vein resection may improve the results of surgical treatment of pancreatic head cancer.
DESIGN: Nonrandomized control trial.
SETTING: Tertiary care referral center. PATIENTS: The study included 149 consecutive patients undergoing macroscopically curative resection for periampullary adenocarcinoma from January 1, 1988, to December 31, 1998.
INTERVENTIONS: A standard resection was performed in 122 cases; an extended lymphadenectomy in 37. Twenty-four patients underwent venous resection. MAIN OUTCOME MEASURES: Data on surgical mortality, morbidity, and postoperative outcome, pathological findings, and long-term survival were analyzed.
RESULTS: In-hospital and 60-day operative mortality was 5.4%. Morbidity was 37.5%. Mortality, morbidity, and postoperative stay were nonsignificantly modified by extended lymphadenectomy or venous resection. Extended resection permitted the identification of a significantly higher percentage of nodal metastases beyond the peripancreatic node groups. In patients undergoing vein resection, a significantly higher rate of positive retroperitoneal margin was found. In the 100 patients with ductal adenocarcinoma, the median overall survival and the 5-year actuarial survival rate were 15 months and 8.4%, respectively. A trend toward a better survival was observed in the first 2 years after operation in the extended resection group compared with the standard resection group. Nodal status was the most powerful predictor of overall survival by multivariate analysis.
CONCLUSIONS: Extended lymphadenectomy and vein resection did not adversely affect postoperative mortality and morbidity. Patients who required a vein resection were less likely to receive a microscopically curative pancreatectomy. Extended resection permitted better pathological staging and was associated with an early advantage in survival, but long-term survival was possible only in patients with favorable prognostic factors.

Entities:  

Mesh:

Year:  2003        PMID: 14662531     DOI: 10.1001/archsurg.138.12.1316

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  32 in total

Review 1.  Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.

Authors:  Terence C Chua; Akshat Saxena
Journal:  J Gastrointest Surg       Date:  2010-04-09       Impact factor: 3.452

2.  Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

Review 3.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Pancreatic resection for pancreatic cancer.

Authors:  Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

5.  Long mesentericoportal vein resection and end-to-end anastomosis without graft in pancreaticoduodenectomy.

Authors:  Ji Zhang; Hong-Gang Qian; Jia-Hua Leng; Ming Cui; Hui Qiu; Guo-Quan Zhou; Jian-Hui Wu; Yong Yang; Chun-Yi Hao
Journal:  J Gastrointest Surg       Date:  2008-12-11       Impact factor: 3.452

6.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

7.  Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.

Authors:  M Carpelan-Holmström; S Nordling; E Pukkala; R Sankila; J Lüttges; G Klöppel; C Haglund
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

8.  Intestinal autotransplantation for neoplasms originating in the pancreatic head with involvement of the superior mesenteric artery.

Authors:  Guosheng Wu; Xin Wang; Qingchuan Zhao; Weizhong Wang; Hai Shi; Mian Wang; Jingson Zhang; Zengshan Li; Daiming Fan
Journal:  Langenbecks Arch Surg       Date:  2016-04-23       Impact factor: 3.445

9.  Extended lymphadenectomy in pancreatic cancer is crucial.

Authors:  Tsutomu Fujii
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

10.  Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence.

Authors:  Wenjie Sun; Cheng N Leong; Zhen Zhang; Jiade J Lu
Journal:  Radiat Oncol       Date:  2010-04-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.